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INTRODUCTION
Haematopoietic stem cell transplantation (HSCT) is an im-
portant standard approach in the treatment of malignant
haematological diseases. HSCT was pioneered using bone-
marrow-derived stem cells by a team at the Fred Hutchinson
Cancer Research Centre in the period from the 1950s
through the 1970s. The work was led by E. Donnall Tho-
mas, and was later recognised with a Nobel Prize in Medi-
cine. The work showed that bone marrow cells infused in-
travenously can repopulate bone marrow and produce new
blood cells.
The first physician who performed a successful human bone
marrow transplant was Robert Good at the University of
Minnesota in 1968.
Successful stem cell transplantation in Latvia, using bone-
marrow-derived stem cells, was carried out in 2001. The
stem cells harvested from peripheral blood are now used
more commonly for both autologous (auto-HSCT) and
allogeneic (allo-HSCT) hematopoietic stem cell transplants
(Fridrichs et al., 2010). Auto-HSCT is used to treat diseases
such as Hodgkin’s lymphoma, non-Hodgkin’s lymphoma,
and multiple myeloma (Gojo et al., 2006; Schmitz et al.,
2007). Despite successful HSCT, viral infections remain one
of the causes of post-transplant morbidity and mortality.
The human beta-herpesviruses — cytomegalovirus (CMV),
human herpesviruses-6 and HHV-7 (HHV-6 and HHV-7)
— are ubiquitous pathogens that infect the majority of
humans. Major complications after allo-HSCT are caused
by CMV and EBV (Anonymous, 2008; Ljungman et al.,
2010; Xuan et al., 2012). Widespread use of antiviral
pre-emptive therapy has markedly diminished the incidence
of CMV-related and EBV complications in transplant pa-
tients during the early period after HSCT.
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The relationship between HHV-6 and HHV-7 reactivation and development of post-autologous
peripheral stem cell transplantation complications was examined. The presence of viral genomic
sequences in whole peripheral blood and cell free plasma was determined by nested PCR,
HHV-6 and HHV-7 load by real-time PCR, virus specific antibodies and cytokines in serum by
ELISA, and HHV-6 variants by restriction endonuclease analysis. Clinical features, reactivation of
viruses and serum TNF-, and IL-6 concentrations were determined in seventy-six patients with
Roseolovirus infection before and after transplantation. Anti-HHV-6 antibodies were found in 62 of
76 (81.6%) patients before transplantation. A significantly higher rate of single HHV-7 infection
was found in patients with viral infection in comparison with single HHV-6 infection (p = 0.0003)
and concurrent (HHV-6 and HHV-7) infection (p = 0.0017). Complications after transplantation de-
veloped in 30.3% of patients and reactivation of viruses was detected in all of these patients. Sig-
nificant increase of HHV-6 and HHV-7 reactivation with simultaneous increase of
pro-inflammatory cytokines serum levels suggests that both viruses may be involved in the devel-
opment of complications after autologous peripheral blood stem cell transplantation via their
immunomodulatory ability. The kinetics of the Roseolovirus reactivation may reflect the potential
role of HHV-7 as a co-factor for HHV-6 activation.
Key words: haematopoietic stem cell transplantation, kinetics of virus reactivation, human
herpesviruses-6 and 7, post-transplantation complication.
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HHV-6 and HHV-7 belong to the family Herpesviride, sub-
family Betaherpesvirinae, genus Roseolovirus (Berneman et
al., 1992). The viruses are ubiquitous (seroprevalence rate
in adults is 60–90%) lymphotropic and immunomodulating
and can be reactivated in immunocompromised and
immunosuppressed hosts (Dockrell and Paya, 2001;
Yamanishi et al., 2001; Lusso et al., 2006). After primary
infection, these viruses establish a state of life-long
subclinical persistence in the human host and are con-
trolled by a functioning immune system (Griffiths et al.,
2000; Ljungman et al., 2008). Roseolovirus displays pri-
mary tropism to CD4+ T cells, where they efficiently repli-
cate, potentially causing immune dysregulation (Dockrell
and Paya, 2001). CD34+ cells, which are a major source of
haematopoietic progenitor cells for transplantation, can be
infected by HHV-6B and HHV-7 in vivo and in vitro, which
may cause myelosuppression in immunocompromised pa-
tients (Movassagh et al., 1996; Mirandola et al., 2000;
Isomura et al., 2003). In 2012, the International Committee
on Taxonomy of Viruses re-classified HHV-6 as separate
viruses HHV-6A and HHV-6B based on their biological
characteristics regarding cell tropism and pathological im-
plications (Ablashi et al., 2014). The specific pathogenicity
of HHV-6A remains poorly understood. HHV-6B reactiva-
tion is a common event in HSCT recipients (40–50%) and
moreover, there is a positive correlation between HHV-6B
infection and CMV reactivation (Zerr et al., 2005;
Boutolleau et al., 2006; Wang et al., 2008). HHV-6 is reac-
tivated early after HSCT (3–4 weeks) and is associated with
a range of clinical symptoms (unexplained fever, skin rash,
delay of monocyte and platelet engraftment, early and late
graft failure, bone marrow suppression) and diseases includ-
ing interstitial pneumonitis, encephalitis and encephalo-
pathy, particularly in patients after peripheral blood HSCT
and bone marrow HSCT (Carrigan et al., 1991; Carrigan
and Knox, 1994; Imbert-Marcille et al., 2000; Yohikava et
al., 2001; Zerr, 2006). The clear association of HHV-7 with
human disease and development of complications after
HSCT has not been recognised. Beta-herpesviruses possess
immunomodulating properties, including the ability to alter
expression of immune activation molecules, modulation of
expression of several cytokines and chemokines and induc-
tion of apoptosis in lymphocytes, which may contribute to
immunosuppression (Lusso, 2006). The ubiquitous nature
of beta-herpesviruses creates conditions for the develop-
ment of concurrent infection and interaction between these
viruses. The kinetics of the activation of these viruses dur-
ing the post-transplantation period suggests that HHV-7 can
act as a co-factor for HHV-6 and CMV reactivation, while
both — HHV-6 and HHV-7 can act as co-factors in CMV
disease development (Miyoshi et al., 2001; Boutolleau et
al., 2003). The prevalence of human herpesvirus reactiva-
tion ranges from 40 to 60% in auto-HSCT patients and usu-
ally occurs within 2–4 weeks (Zerr et al., 2005). HHV-6
and HHV-7 have been frequently detected in allo-HSCT re-
cipients. Asymptomatic HHV-6 reactivations predominate
in the post-HSCT setting. Previously, we investigated the
role of HHV-6 and HHV-7 in development of complica-
tions after renal transplantation and showed that HHV-7
acts as a co-factor for HHV-6 and CMV reactivation, while
both HHV-6 and HHV-7 act as co-factors in the patho-
genesis of CMV disease, acute rejection and chronic
allograft nephropathy (Chapenko et al., 2001, Folkmane et
al., 2001, Chapenko et al., 2009). In the present study we
examined presence of beta-herpesviruses and EBV infection
in patients with auto- and allo-transplatation of peripheral
blood stem cells, which allowed to estimate significance of
infection activation of each virus and its relationship with
development of complications.
The aim of this study was to examine: 1) the presence of
HHV-6 and/or HHV-7 infection in patients before auto-
HSCT; 2) frequency of reactivation of these viruses in early
period after auto-HSCT; 3) the potential interactions be-
tween reactivation of the viruses and development of
post-transplant complications; 4) potential relationship be-
tween reactivation of these viruses by co-infection.
MATERIALS AND METHODS
Patients. During the period from 2006 until 2010 and from
2013 until 2015, Roseolovirus infection was studied in 76
patients (44 females, 32 males; mean age 34.1 ± 10.7) who
were placed in the Chemotherapy and Hematology Clinic of
Rîga East University Hospital and underwent auto-HSCT.
The patients group was composed of 37 patients with Hodg-
kin’s disease, 16 with non-Hodgkin’s lymphoma, and 23
patients with myeloma. A summary of their characteristics
including age, underlying disease, pre-transplant chemo-
therapy, the average number of cycles of chemotherapy be-
fore HSCT for each patient, serology CMV and EBV, con-
ditioning regimens, amount of CD34+ cells in grafts,
duration of severe neutropenia (absolute neutrophil count
< 0.5 × 103/ul), and post-transplant complications, are
shown in Table 1. Stem cells for grafts were harvested be-
fore HSCT from peripheral blood in the period during treat-
ment with non-myeloablative chemotherapy and mobilisa-
tion with granulocyte-colony-stimulating factor (G-CSF) (5
µg/kg on days 4–14). Patients with lymphoma before
auto-HSCT had received myeloablative/conditioning ther-
apy by BEAM protocol (carmustin, cytosar, etoposide,
melphalan); myeloma patients received myeloablative/con-
ditioning therapy with melphalan 200 mg/m². All patients
for prophylaxis of Gram-positive and Gram-negative infec-
tions received (sulfametoxasolum/trimepthoprimum 960 mg
b.i.d. a day orally 2 times per week for 3 months), for fun-
gal (fluconazole 150 mg, orally or 200 mg i/v, 3 weeks) and
viral infections (valacyclovir 500 mg/m2 2× day, orally or
aciclovir 400 mg 2× day, orally, for one month) after
HSCT. Blood samples from the patients were collected be-
fore auto-HSCT as the baseline and for 3 months after
HSCT (day 7 to 10 and on days 14, 28, 56, 84). Aliquots
were stored at –80 °C before use. Clinical events examined
in association with active viral infection were fever,
skin rash, pneumonitis, partial bone marrow suppression,
central nervous system dysfunction, and gastroenteritis (di-
arrhea).
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The cohort was established with the approval of the Ethics
Committee of the Rîga Stradiòð University and all partici-
pants were informed and gave consent prior to the examina-
tion.
HHV-6, CMV, EBV serology. Serum samples from pa-
tients before and after HSCT were tested for HHV-6 IgG
class antibodies using HHV-6 IgG ELISA kits (Panbio, Sin-
namon Park, Australia), according to the manufacturer’s
recommendations. The serum samples before HSCT were
tested for CMV IgM, IgG class antibodies using ELISA anti
CMV IgM or IgG/Enzygnost Anti-CMV IgM or IgG (Dade
Behring, Germany) and EBV IgM, IgG class antibodies us-
ing ELISA IgM or IgG LIAISON EBV IgM, LIAISON
VCA IgG (DiaSorin, Italy), according to the manufacturer’s
recommendations.
Nested polymerase chain reaction (nPCR). nPCR was
used for the detection of viral genomic sequences in DNA
isolated from whole peripheral blood (WPB) and plasma
(markers of persistent and active infection, respectively).
Total DNA was isolated from 0.5 ml fresh whole blood by
phenol-chloroform extraction. DNA purification was made
from 200 µl cell free blood plasma QIAamp Blood Kit
(QIAGEN, Hilden, Germany) was used. The plasma sam-
ples were treated with Desoxyribonuclease I (Fermentas,
Vilnius, Lithuania) before DNA purification. To assure
quality of the WPB DNA and to exclude contamination of
plasma DNA by cellular DNA, a globin PCR was per-
formed. PCR amplification for the viruses was carried out
using 1 µg DNA and 10 µl plasma DNA (corresponding to
100 µl of plasma). The detection of HHV-6 and HHV-7
DNA was performed according to Secchiero et al. (1995)
and Berneman et al. (1992), respectively. Positive (virus ge-
nomic DNA, Advanced Biotechnologies Inc, Columbia,
MD, USA) and negative (DNA without virus-specific se-
quences) as well as water controls were included in each ex-
periment.
Quantitative real-time polymerase chain reaction.
HHV-6 load before HSCT was determined in WPB sam-
ples positive for viral DNA (according to nPCR data) using
a HHV-6 Real-TM Quant kit (Sacace, Biotechnologies, It-
aly) and Applied Biosystems 7500 Real-time PCR System
(Applied Biosystems, USA, according to the manufacturer's
instruction. The WBL with ethylenediaminetetraacetic acid
from patients after HSCT were tested for CMV DNA quan-
tified by Real Time PCR (Artus CMV LC PCR Kit, Qiagen,
Germany) and EBV DNA quantified by Real Time PCR
(Artus EBV LC PCR Kit, Germany), according to the
manufacturer’s recommendations.
T a b l e 1










Sex, M : F 12 : 25 10 : 6 10 : 13
Age, median years (range) 29.8 (range 17–52) 36.8 (range 16–49) 43.4 (range 19–60)
Pre-transplant chemotherapy IVE (n = 23)
DexaBEAM (n = 10)
BEACOPP (n = 2)
ASHAP (n = 1)
MINE (n = 1)
CHOP like (n = 5)
IVE (n = 11)
Endoxan (n = 12)
VAD (n = 3)
Bor/Dex (n = 5)
Bor/Cy/Dex (n = 3)
The average number of cycles of chemotherapy before
transplantation for each patient
3 4 4
Conditioning regimens BEAM (n = 37) BEAM (n = 16) Melphalan (n = 23)
CMV IgG seropositive before HSCT







EBV IgG seropositive before HSCT







Neutropenia .5x109/l, days 9.10 (range 5–14) 11.20 (range 8–14) 8.22 (range 4–12)








Complications 12 4 7
DexaBEAM, carmustine, etoposide, cytorabine, melphalan, dexamethasone; BEAM, carmustine, etoposide, cytorabine, melphalan; BEACOPP, etoposide,
doxorubicine, cyclophosphamide, bleomycine, procarbazine, vincristine, prednisolone; ASHAP, doxorubicine, cisplatin, cytorabine, methylprednisolone;
IVE, ifosfamide, etoposide, doxorubicin; MINE, mitoxantrone, ifosfamide, etoposide; CHOP like, cyclophosphamide, doxorubicin, prednisolone,
vincristine; VAD, vincristine, doxorubicin, dexamethasone; Bor/Dex, bortezomib, dexamethasone; Bor/Cy/Dex, bortezomib, cyclophosphamide, dexametha-
sone; G-CFS, granulocyte colony stimulating factor; HSCT, Hematopoietic stem cell transplantation; CMV, cytomegalovirus; EBV, Epstein Barr virus
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Restriction endonuclease analysis. Restriction endonucle-
ase analysis was carried out using enzyme HindIII (Fermen-
tas, Vilnius, Lithuania), which cuts HHV-6B 163 bp am-
plimer into two fragments: 66 bp and 97 bp, and does not
cut HHV-6A amplimer. This difference allows to distin-
guish HHV-6A and HHV-6B variants. HHV-6B was tested
for in all WPB DNA samples from patients with HHV-6 in-
fection.
Assays for cytokine determination. Platinum ELISA kits
Human IL-6 and TNF-alfa (AviBion, Helsinki, Finland)
were used for the detection of TNF-, and IL-6 levels in se-
rum samples of patients PCR-negative for viral infection,
with persistent infection in latent phase, and active viral in-
fection. The sensitivity of the ELISA assay was 2 pg/ml for
TNF- and for IL-6. All samples were tested in duplicate.
Statistical analysis. Significant differences in the preva-
lence of HHV-6 and HHV-7 infection before and after
transplantation were determined using the Fisher's exact
test. The non-parametric Wilcoxon’s matched-pairs signed
test was performed using GraphPad Prism Version 6.0
(GraphPad Software Inc., La Jolla, CA, USA) for analysis
of HHV-6 load in WPB of patients with persistent infection
in latent phase and active phase. The serum cytokine level
was expressed as mean ± SD. SPSS software was used to
assess the continuous variables (cytokine levels) with a
value of p < 0.05 considered as significant.
RESULTS
Specific anti-HHV-6 IgG class antibodies were found in se-
rum samples of 62 of 76 (81.6%) pre-transplant patients.
CMV and EBV IgM antibodies were not found in any of the
patients. After HSCT, CMV, and EBV DNA were deter-
mined quantitatively weekly. Active CMV and EBV infec-
tion was not recorded in any of the patients.
HHV-6 and/or HHV-7 genomic sequences were found in
samples isolated from WPB from 68 of 76 (89.5%) of the
pre-transplant patients using nPCR (Table 2). In the patients
with viral infection, a significantly higher rate of single
HHV-7 infection was found in comparison with single
HHV-6 infection (p = 0.0003) and concurrent (HHV-6+
HHV-7) infection (p = 0.0017). HHV-6B was recorded in
all 26 WPB DNA samples from patients with HHV-6 infec-
tion. Viral genomic sequences were found in plasma DNA
samples from 5 out 68 (7.4%) patients before transplanta-
tion (Table 2). Of them, HHV-6 plasma viremia was de-
tected in one patient, HHV-7 plasma viremia in 3 patients
with single HHV-7 infection and simultaneous HHV-6 and
HHV-7 plasma viremia in one patient with concurrent
(HHV-6 and HHV-7) infection.
The frequency of plasma viremia was significantly higher in
patients after transplantation (25/68, 36.7%) in comparison
with the frequency before transplantation (p = 0.00003)
(Table 2). No significant difference in the rate of active con-
current HHV-6 and HHV-7 infection occurred in patients
after transplantation compared to the rate of patients before
transplantation (p = 0.180).
HHV-7 plasma viremia was found in 22 patients (17 with
single HHV-7 infection and 5 with concurrent infection)
(Table 2). HHV-6 reactivation was found in 8 patients (3
with single infection and 5 with concurrent infection).
The HHV-6B genomic sequence was identified in all
plasma DNA samples from patients with HHV-6 plasma
viremia.
The mean number of days before detecting HHV-7 and
HHV-6 reactivation was 11 days (range: 7–14 days) for
HHV-7 and 27 (range: 10–34 days) for HHV-6. Median
HHV-6 load in WPB DNA of the patients examined in the
period of persistent infection in latent phase before trans-
plantation was 5657 copies/µg DNA [irangeinterquartile
range (IQR): 4514–9723 copies/µg DNA] and in the period
of active phase infection after transplantation 59439 cop-
ies/µg DNA (IQR: 40309–63168 copies/µg DNA). There is
no standard threshold for clinically significant HHV-6 viral
load and development of post-transplant complications.
CMV and EBV load  195 copies/ml and  240 copies/ml,
respectively, are considered to indicate persistent infection
in latent phase, and larger loads occur in cases of active in-
fection. However, virus activation is not always linked to
development of complications.
To explore the effect of HHV-6 and/or HHV-7 reactivation
on cytokine levels, serum pro-inflammatory TNF-, and
IL-6 cytokine levels were determined in 25 patients (Table
3). TNF- and IL-6 levels were significantly higher in pa-
tients with viruses reactivation than in patients with HHV-7
and HHV-6 persistent infection in latent phase (p < 0.0001,
p = 0.01, respectively). The level of TNF- but not IL-6
was significantly higher in patients with simultaneous
HHV-6 and HHV-7 reactivation (p < 0.0001, p < 0.0001,
respectively). Although the level of IL-6 was higher in pa-
tients with simultaneous HHV-6 and HHV-7 reactivation, in
comparison with the level in patients with latent concurrent
infection, the difference was not significant (p = 0.054).
Clinical complications (febrile neutropenia, gastroenteritis
(diarrhea), pneumonitis)) were detected in 23 of 76 (30.3%)
transplant patients (Table 4). Febrile neutropenia was diag-
T a b l e 2
PRESENCE OF BETA-HERPESVIRUSES GENOMIC SEQUENCES IN
WPB AND IN PLASMA DNA SAMPLES OF PATIENTS BEFORE
AND AFTER TRANSPLANTATION DETECTED BY NPCR (n = 76)
Viral infection Before transplantation After
transplantation
WPB Plasma Plasma
Single HHV-6 4/76 1/4 3/4




Negative for all 8/76 0/8
WPB, whole peripheral blood; nPCR, nested polymerase chain reaction
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nosed in most patients (14/23, 60.86%) in the early
post-transplant period (7–14 days), and febrile neutropenia
combined with gastroenteritis (diarrhea) and/or pneumonitis
development (7/23, 30.43%). HHV-7 reactivation was de-
tected in 8 of these 23 patients (5/8 with febrile neutropenia
and 3/8 with gastroenteritis). Pneumonitis was detected in
10 of 23 patients (43.47%) and gastroenteritis in 11 of 23
patients (47.82%). On average HHV-6 and HHV-7 reactiva-
tion was detected 15.8 and 10.2 days after transplantation,
respectively, in the early post-transplant period and a longer
neutropenic period was observed in patients who had com-
plications.
T a b l e 3
SERUM/PLASMA EXPRESSION LEVELS OF CYTOKINES IN THE






Negative (n = 8) 2.05 ± 1.24 3.25 ± 1.89
Latent (n = 43) 12.38 ± 2.96 4.39 ± 0.48
Active (n = 25)
HHV-6 (n = 3)
HHV-7 (n = 17)









T a b l e 4




















1 HD DexaBEAM/BEAM 5 - + (7) - febrile neutropenia +
gastroenteritis(diarrhea)
2 HD DexaBEAM/BEAM 9 - + (7) + (21) pneumonia
3 HD DexaBEAM/BEAM 8 - + (7) - febrile neutropenia
4 HD DexaBEAM/BEAM 10 + + (10) - febrile neutropenia
5 HD MINE/BEAM 10 - + (10) + (10) febrile neutropenia +
pneumonia
6 HD IVE/BEAM 10 - + (7) + (14) febrile neutropenia
7 HD IVE/BEAM 13 - + (14) + (14) gastroenteritis(diarrhea) +
pneumonia
8 HD IVE/BEAM 8 - + (10) + (21) febrile neutropenia +
pneumonia
9 HD IVE/BEAM 14 + + (9) - febrile neutropenia
10 HD IVE/BEAM 8 + + (10) - febrile neutropenia +
pneumonia
11 HD IVE/BEAM 9 - - + (10) febrile neutropenia
12 HD IVE/BEAM 10 + + (9) - febrile neutropenia
13 NHL IVE/BEAM 13 - + (7) + (14) gastroenteritis(diarrhea)
14 NHL IVE/BEAM 14 + + (12) - pneumonia
15 NHL IVE/BEAM 11 + + (10) + (10) febrile neutropenia +
gastroenteritis(diarrhea) +
pneumonia
16 NHL IVE/BEAM 10 - +(13) - febrile neutropenia
17 MM Endoxan/Melphalan 6 - + (10) + (28) gastroenteritis(diarrhea) +
pneumonia
18 MM Endoxan/Melphalan 11 - + (8) + (21) febrile neutropenia +
gastroenteritis (diarrhea)+
pneumonia
19 MM Endoxan/Melphalan 10 - + (21) - gastroenteritis(diarrhea)
20 MM Endoxan/Melphalan 12 + + (8) + (21) pneumonia +
gastroenteritis(diarrhea)
21 MM Endoxan/Melphalan 9 + + (10) + (14) gastroenteritis(diarrhea)
22 MM Endoxan/Melphalan 10 - + (13) + (14) gastroenteritis(diarrhea)
23 MM Endoxan/Melphalan 7 + + (14) + (10) febrile neutropenia +
gastroenteritis(diarrhea)
HD, Hodgkin’s disease; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; DexaBEAM, carmustine, etoposide, cytorabine, melphalan, dexametha-
sone; BEAM, carmustine, etoposide, cytorabine, melphalan; IVE, ifosfamide, etoposide, doxorubicin; MINE, mitoxantrone, ifosfamide, etoposide; - negative;
+ positive; ( ) - days after transplantation
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DISCUSSION
Autologous peripheral blood progenitor cell transplantation
is used as a standard of care in patients with Hodgkin's lym-
phoma, non-Hodgkin's lymphoma and multiple myeloma in
the Chemotherapy and Haematology Clinic. Evidence of a
correlation between beta-herpesviruses reactivation and
various clinical manifestations has accumulated mainly
from studies on solid organs (Chapenko et al., 2001; Rason-
able et al., 2010) and allogeneic bone marrow and hemato-
poietic stem cell transplantations (Rieger et al., 2009). In
this study we examined incidence of HHV-6 and HHV-7 in-
fection and frequency of virus reactivation before and after
auto-HSCT, HHV-6 load and the relationship between virus
reactivation and development of clinical complications in
early period after auto-HSCT.
Our results show high frequency of HHV-6 and HHV-7 per-
sistent infection in stem cell transplant patients in Latvia,
which indicates a need to determine the risk of infection ac-
tivation of these viruses after auto-HSCT and the validity of
antiviral prophylaxis and pre-emptive therapy application.
All HSCT recipients should be tested for the presence of se-
rum anti-HHV-6 IgG class antibodies before HSCT, to de-
termine the risk for primary herpesvirus infection and reac-
tivation after HSCT. The study showed high frequency of
HHV-6 seroprevalence (81.8%) and wide prevalence
(89.5%) of persistent beta-herpesviruses infection among
patients before HSCT, thus confirming the ubiquity of this
virus. Considering that Roseoloviruses are ubiquitous, this
study showed that single HHV-7 and concurrent HHV-6
and HHV-7 persistent infection in latent phase were preva-
lent among these patients. The obtained data allow to deter-
mine the risk of subsequent virus reactivation after trans-
plantation and validity of antiviral prophylaxis and pre-
emptive therapy application. Single HHV-7 and concurrent
HHV-6 and HHV-7 persistent infections are highly preva-
lent also in Latvian blood donors (Kozireva et al., 2001).
The study showed that active single HHV-6 infection (1/68,
1.5%), single HHV-7 (3/68, 4.4%) and concurrent HHV-6
and HHV-7 (1/68, 1.5%) are presented in the patients before
transplantation without clinical manifestations. This sug-
gests that the virus reactivation can be a consequence of the
application of pre-transplant chemotherapy. Active single
HHV-7 infection only, but not active single HHV-6 or con-
current HHV-6 and HHV-7 infection, has been detected
also in 10.6% of Latvian blood donors (Kozireva et al.,
2001).
HHV-6B was detected in all WPB and plasma DNA sam-
ples from patients with HHV-6 infection. This suggests that
either the HHV-6A variant occurs infrequently in these pa-
tients or it may be limited by sites other than the peripheral
blood. Possibly the obtained results may be explained by
geographical distributions of the variants (Èistjakovs et al.,
2009).
The frequency of Roseolovirus reactivation considerably in-
creased after transplantation (36.8%), compared to that be-
fore transplantation (7.4%), and the rate of single HHV-7
infection was also prevalent in patients after HSCT. Our ex-
perience has shown that Valacyclovir, which is used for an-
tiviral prophylaxis, is not sufficiently effective to prevent
HHV-7 reactivation. Foscarnet, ganciclovir and cidofovir
have been shown to inhibit HHV-6 replication in vitro
while ganciclovir prophylaxis was associated with a signifi-
cant decrease in frequency of HHV-6, but not of HHV-7 re-
activation in stem cell transplant patients (Rapaport et al.,
2002; Ongradi et al., 2010). Ganciclovir, cidofovir and
foscarnet have variable activity against HHV-6 in vitro and
may have a role in treatment of HHV-6-associated diseases.
Presently, there is no data to support recommendations for
monitoring of potential HHV-7-associated disease (Anony-
mous, 2008; Zaia et al., 2009; Anonymous, 2015). HHV-6
reactivation is confirmed by viral sequence detection in
plasma DNA samples, and concomitant increase of HHV-6
load in WPB and HHV-7 reactivation by plasma viremia
detection. Standardised quantitative PCR assays for
Roseoloviruses are lacking, which limits the optimal use of
this assay in the setting of transplantation. At present, the
question of potential impact between beta-herpesviruses in
cases of concurrent infection is pending. In this study,
HHV-6 reactivation was found in patients with concurrent
HHV-6 and HHV-7 infection and each virus had a definite
temporal profile of detection. The reactivation of HHV-7 is
observed before HHV-6 reactivation, which may suggest
potential interaction between these viruses. These results
are in accordance with those obtained in previous studies
conducted in vitro (Katsafanas et al., 1996) and in vivo
(Maeda et al., 2000; Boutolleau et al., 2003; Hall et al.,
2006). However, Sassenscheidt et al. (2006), Humar et al.
(2009), Tormo et al. (2010) did not find evidence for poten-
tial interaction between HHV-6, HHV-7, and CMV.
After auto-HSCT, the risk of bacterial infections and mor-
tality rate are lower due to the usually less intensive mu-
cositis and the shorter neutropenia. In the autologous set-
ting, the infection risk almost completely disappears after
neutrophil recovery. Only 30–35% of febrile episodes in
neutropenic patients can be documented microbiologically;
in the remaining cases, the cause of the fever cannot be
demonstrated (Anonymous, 2012).
Although the precise mechanism by which beta-herpes-
viruses impair immunologic function is not completely
clear, previous investigations have shown that these viruses
are very effective modulators of immune response, mainly
by modulating the production of pro-inflammatory
cytokines, including TNF- and IL-1 (Lusso, 2006). We
found significantly higher expression levels of TNF-, and
IL-6 in serum samples from patients with virus reactivation
than in those from patients with persistent infection in latent
phase. Effect of HHV-6 and/or HHV-7 reactivation on IL-6
synthesis is measured unequally (Atedzoe et al., 1999;
Fujita et al., 2008). The results of this study showed that
HHV-7 reactivation, but not co-reactivation of both viruses,
induces significant increase of IL-6 production. The impact
of HHV-6 and/or HHV-7 reactivation on clinical episodes
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in the early period after auto-HSCT is not clear. The risk of
viral infection activation is associated with severe neutro-
penia, which is induced by myeloablative chemotherapy be-
fore HSCT. Clinical complications were found in 33.8% of
patients and in all of them severe neutropenia and
Roseolovirus infection reactivation were found. Severe
neutropenia was observed, however also in patients without
beta-herpesviruses infection, which might be associated
with specific pre-transplant therapy. The development of
complications was detected only in patients with active
beta-herpesvirus infection, suggesting possible influence of
virus reactivation on strength of immunosuppression. These
results are in accordance with those reported by Razonable
et al. (2003). Carrigan et al. (1993) reported two cases of
severe interstitial pneumonitis associated with HHV-6 in-
fection in bone marrow transplant recipients. Zerr et al.
(2012) reported that relatively mild immunosuppression as-
sociated with HSCT might become more profound in pa-
tients whose pretransplant treatment already resulted in im-
munodeficiency. The patients diagnosed with HHV-6
reactivation are presented with high unexplained fever. In
most cases of active HHV-7 infection no side symptoms are
observed; however, HHV-7 reactivation also leads to or is
associated with a number of symptoms, including acute fe-
brile respiratory disease, fever, rash, vomiting, diarrhoea,
low lymphocyte counts and febrile seizures (Govern and
Barbara, 2016). High frequency of HHV-6 and HHV-7 in-
fection activation with simultaneous increase of pro-inflam-
matory cytokine serum levels suggests that both viruses
may be involved in the development of complications in the
early period after auto-HSCT process via their immuno-
modulatory ability.
The kinetics of the virus reactivation may reflect the poten-
tial role of HHV-7 as a co-factor of HHV-6 activation. Our
data suggest that valacyclovir used in for antiviral prophy-
laxis and therapy is not sufficiently effective to prevent
HHV-6 and HHV-7 infection activation after auto-HSCT.
However, prophylaxis with acyclovir or valaciclovir in stem
cell transplantation can be recommended to decrease the
risk of herpesviruses infection reactivation during the early
phase of transplant (Ljungman et al., 2011; Anonymous,
2008).
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HHV-6 UN HHV-7 INFEKCIJAS IETEKME UZ PÇCTRANSPLANTÂCIJAS KLÎNISKO GAITU UN KOMPLIKÂCIJU ATTÎSTÎBU
PACIENTIEM PÇC AUTOLOGAS CILMES ÐÛNU TRANSPLANTÂCIJAS
Autologâ hemopoçtisko cilmes ðûnu transplantâcija ðobrîd tiek izmantota kâ standarta ârstçðanas metode pacientiem ar Hodþkina slimîbu,
ne-Hodþkina limfomu un mielomas slimîbu. Ðajâ darbâ tika pçtîta HHV-6 un/vai HHV-7 infekcijas maríieru klâtbûtne pacientiem pirms
autologâs cilmes ðûnu transplantâcijas, ðo vîrusu reaktivâcijas bieþums agrînajâ pçctransplantâcijas periodâ un ietekme uz komplikâciju
attîstîbu pçc autologâs perifçro asiòu cilmes ðûnu transplantâcijas. Vîrusu genoma sekvenèu klâtbûtne DNS, kas izdalîta no pilnâm
perifçrajâm asinîm, tika noteikta ar polimerâzes íçdes reakciju (polymerase chain reaction, PCR), HHV-6 slodze ar reâlâ laika PCR,
vîrusspecifiskâs antivielas un citokîni serumâ ar ELISA, HHV-6 varianti ar endonukleâzes restrikcijas analîzi. Pçtîjumâ iekïauti 76
pacienti, no kuriem 68 konstatçta Roseola vîrusu infekcija. Tika novçrtçta vîrusu reaktivâcija, mijiedarbîba ar proinflamatorajiem jeb
iekaisuma citokîniem TNF alfa un IL-6, kâ arî pçctransplantâcijas klîniskâ gaita un komplikâciju attîstîba. Anti-HHV-6 IgG klases
antivielas tika konstatçtas 62 no 76 (81,6%) pacientiem pirms autologâs cilmes ðûnu transplantâcijas. Visiem pacientiem pirms
transplantâcijas tika atrastas arî specifiskâs anti-CMV un anti-EBV IgG klases antivielas. Pacientiem pçc transplantâcijas tika konstatçta
nozîmîgi bieþâka HHV-7 aktivâcija, salîdzinot ar HHV-6 (p = 0,0003) un vienlaicîgas HHV-6 + HHV-7 infekcijas aktivâciju (p = 0,0017).
Komplikâcijas pçc transplantâcijas novçroja 30,3% pacientu, un visiem pacientiem ar komplikâcijâm tika konstatçta HHV-6 un /vai
HHV-7 reaktivâcija. Ievçrojams HHV-6 un HHV-7 reaktivâcijas pieaugums ar vienlaicîgu iekaisuma citokînu lîmeòa palielinâðanos
serumâ, òemot vçrâ minçto vîrusu imûnmodulçjoðâs spçjas, liecina, ka abi vîrusi ir iesaistîti komplikâciju attîstîbâ pçc autologâs perifçro
asiòu cilmes ðûnu transplantâcijas. Ðie dati ïauj domât, ka HHV-7 darbojas kâ HHV-6 aktivâcijas kofaktors pçctransplantâcijas pacientiem.
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